Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Samsung Bioepis Co.,Ltd.

Home Clinical Trial Sponsors and OrganizationsSamsung Bioepis Co.,Ltd.

Samsung Bioepis Co.,Ltd.

Kalkbrænderiløbskaj 6, København Ø, Hovedstaden, Denmark

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

13

5 active

Approvals

4

Total approvals

Agencies

1

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 3

9

69.2%

Phase 1

2

15.4%

Phase 2

1

7.7%

Phase 4

1

7.7%

Trial Status Distribution

Active, not recruiting

2

15.4%

Completed

4

30.8%

Not yet recruiting

3

23.1%

Recruiting

4

30.8%

Clinical Trials

Trials sponsored by this organization (13)

Study which tests 2 medications (SB27, Keytruda) to compare how effective, safe and well tolerated in a large number of metastatic non-squamous non-small cell lung cancer patients

Sep 2023616 participants

Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy

Sep 2023135 participants

A Long-term Follow-up Study for Cardiac Safety in the Patients with HER2 positive Breast Cancer Who Have Completed the SB3-G31-BC study.

Not yet recruiting

Feb 2020612 participants

A study to compare SB12 (proposed eculizumab biosimilar) with SolirisÂ® in patients with the disease Paroxysmal Nocturnal Haemoglobinuria

Active, not recruiting

Aug 201950 participants

A clinical trial study to compare the effects of two drugs SB11 (study drug) and LucentisÂ® in subjects who have age related loss of vision

Jul 2018704 participants

A clinical study to compare the efficacy and safety of SB3 (proposed trastuzumab biosimilar) and HerceptinÂ® in women with HER2 Positive Early or Locally Advanced Breast Cancer.

Oct 2014806 participants

An open-label, single group, single-dose clinical study to evaluate the usability of the pre-filled syringe (PFS) of SB11 in trial participants with Neovascular Age-Related Macular Degeneration (AMD), Macular Oedema Secondary to Retinal Vein Occlusion (RVO), or Myopic Choroidal Neovascularization (mCNV)

30 participants

A clinical study to compare the efficacy and safety of SB3 (proposed trastuzumab biosimilar) and HerceptinÂ® in women with HER2 Positive Early or Locally Advanced Breast Cancer.

104 participants

Page 1 of 2

Approvals

Approvals by Agency

SFDA

Saudi Food and Drug Authority

4

Approvals

Recent Approvals

HADLIMA 40MG/0.8ML INJECTION IN PRE-FILLED SYRING

HADLIMA 40MG/0.8ML INJECTION IN PFP

News

No news articles found

On this page

Overview
Clinical Trials13
Approvals4
News

Back to Organizations